JP6139217B2 - Method for producing D-amino acid - Google Patents

Description

  The present invention relates to a method for producing a D-amino acid. The D-amino acid produced by the method can be used by blending it with a composition such as a pharmaceutical, a quasi drug, a cosmetic, a food, and a feed.

  There are D-forms and L-forms of amino acids, but it has been considered that most amino acids present in the human body are L-forms. However, advances in measurement technology have revealed that some D-amino acids are present in the human body and that physiological actions of D-amino acids are different from those of L-amino acids.

  Studies on D-amino acids have mainly been approaches from physiological and medical viewpoints such as the relationship with neurotransmission and hormone regulation. For example, since D-serine is ubiquitous in the central nervous system and shows a strong positive correlation with the distribution of NMDA receptor channels, its action has attracted attention. NMDA receptors are known to increase memory and learning ability when their functions increase. And it has become clear that D-serine or D-alanine enhances NMDA receptor activity (Non-patent Document 1).

  It is known that D-alanine is involved in the control of blood glucose level (Non-patent Document 2) and has a collagen production promoting action (Patent Document 1). Moreover, since D-proline reduces UV damage, it is expected not only to suppress wrinkles involving UV light but also to be applied to cataract as a pharmaceutical (Patent Document 2).

  In addition, it is clear that D-amino acid is present in human skin (horny layer), D-aspartic acid decreases with aging, and D-aspartic acid has a skin beautifying effect superior to L-aspartic acid. (Non-Patent Document 3). Because of the above effects, products rich in D-aspartic acid are currently on the market.

  In addition, D-aspartic acid is present in pineal parenchymal cells and is involved in enhancement of testosterone production in testicular Leydig cells, suggesting the possibility of being involved in the improvement of reproductive function (non-patent literature). 4).

  Since D-histidine has an anti-obesity action by suppressing appetite, it is expected to be used for weight control such as metabolic control (Non-patent Document 5).

  On the other hand, in recent years, approaches from the food field have also begun for D-amino acids. Although it is known that the taste of free amino acids differs greatly between L-form and D-form, D-form can be used as a flavor improving agent as well as L-form (Patent Document 3). And fermented foods such as cheese, yogurt, black vinegar or sake contain abundant D-amino acids and are considered to play a role in the taste of fermented foods.

Non-Patent Document 6, Japanese sake kimoto building, there is a high tendency D- amino acid concentration contained, they D- amino acids to enhance the flavor and overall evaluation of sake, and their D- amino acid raw that the original origin of lactic acid bacteria has produced, it has been revealed.

As mentioned above, D-amino acids are expected to have various uses from research related to physiology / biochemistry, food science, etc., and are considered to be used as new functional ingredients in the fields of foods, pharmaceuticals, etc. ing. However, D-amino acids are optically active amino acids, and it is known that it is difficult to produce optically pure D-amino acids.

  So far, it has been reported that many D-amino acids are present in the cells of bacteria including bifidobacteria and lactic acid bacteria (Non-patent Document 7). Then, although the method of manufacturing D-amino acid using the said bacterium or the enzyme which the said bacterium produces is known (patent documents 4 and 5), D body reported to exist in a bacterial cell. Since the ratio of the D-form to the L-form is not high, the efficiency is not good. Furthermore, since D-amino acids can be used as materials for pharmaceuticals, quasi drugs, cosmetics, foods, feeds, and the like, high purity ones are required. There was a possibility that not a few impurities were mixed.

International Publication No. 2011/040363 International Publication No. 2010/113925 International Publication No. 2012/057084 JP 2010-154774 A JP-A-11-113582 Japanese Patent Laying-Open No. 2005-003558

Takaaki Matsui, Kinki University Medical Journal, 1996, Vol. 21, No. 1, p. 115-124 Morikawa A, et al., Biochem Biophys Res Commun, 2007, 355 (4): 872-6 Health pro News from Nikkei Health, “D-amino acid has a beautifying effect, Shiseido announces that it works in the stratum corneum and the dermis and improves moisture content”, [online], June 25, 2010, [February 28, 2013] Search], Internet <URL: http://nhpro.nikkeibp.co.jp/nh/pro/> Macchia G, et al., "DL-Aspartic acid administration improves semen quality in rabbit bucks.", Animal Reproduction Science, 2010, 118 (2-4): 337-343 Yuji Yamamoto, “Analysis of physiological functions of D-type amino acids in vivo”, Urakami Foundation Research Report, 2007, Vol. 15, p. 33-42 Yoshitaka Gogami et al., Trace Nutrients Research 29, 2012, 1-6 HANS BRUCKNER, et al., CHIRALITY, 1993, 5: 385-392 Kenji Hamase, et al., Journal of Chromatography A, 2010, Vol.1217, 1056-1062 Kenji Hamase et al., “Development of a selective analysis method for trace D-amino acids in mammals”, Analytical Chemistry, 2004, Vol. 53, no. 7, p. 677-690

  An object of the present invention is to provide a novel technique for producing a D-amino acid using a bacterium that has not been known to secrete a D-amino acid. It is another object of the present invention to provide a method for producing a D-amino acid with high efficiency.

As a result of intensive studies to solve the above problems, the present inventors have found that bacteria belonging to the genus Bifidobacterium secrete D-amino acids, and that bacteria belonging to the genus Bifidobacterium are among the bacteria belonging to the genus Bifidobacterium. Has found that there are species whose secreted amount of D-form is much higher than that of L-form, and has completed the present invention.

That is, the present invention relates to the following matters.
[1] culturing bacteria belonging to the genus Bifidobacterium in a medium; and
Separating the D-amino acid secreted into the culture medium after the culture and the bacteria, and recovering a fraction containing the D-amino acid from the medium;
A process for producing a D-amino acid comprising:
[2] The production method according to [1], wherein the fraction containing the D-amino acid is collected from the medium after removing the bacteria from the medium.
[3] The production method according to [1] or [2], wherein the fraction containing the D-amino acid satisfies the following relational expression (1).
[D-amino acid secretion amount] / ([D-amino acid secretion amount] + [L-amino acid secretion amount]) ≧ 0.5 (1)
[4] The [1] to [1], wherein the D-amino acid is one or more D-amino acids selected from the group consisting of D-histidine, D-asparagine, D-proline, D-serine, and D-alanine. [3] The production method according to any one of [3].
[5] The bacterium belonging to the genus Bifidobacterium is one or more bacteria selected from the group consisting of Bifidobacterium longum species, Bifidobacterium breve species, and Bifidobacterium bifidum species The production method according to any one of the above [1] to [4].
[6] A composition comprising a fraction containing a D-amino acid produced by the production method according to any one of [1] to [5].

According to the present invention, a D-amino acid can be produced using a bacterium belonging to the genus Bifidobacterium that has not been known to secrete a D-amino acid.
Further, in a preferred embodiment, by using a Bifidobacterium bacterium having a high ratio of [D-amino acid secretion amount] / ([D-amino acid secretion amount] + [L-amino acid secretion amount]), it is highly efficient. A method for producing D-amino acids is provided.
Furthermore, since the bacterium used in the present invention is a bacterium belonging to the genus Bifidobacterium having a long dietary experience, so-called bifidobacteria, the D-amino acid produced according to the present invention has high safety, and is used as a medicine, pharmaceutical part It can be suitably used for compositions such as external products, cosmetics, food and drink, and feed.

It is a chromatogram including the peak of serine (a state in which L-form and D-form are mixed) separated by a first-dimensional reversed-phase column. The vertical axis represents fluorescence detection intensity, and the horizontal axis represents elapsed time. It is a chromatogram containing the peak of D-serine and L-serine separated by the optical isomer separation column of the second dimension. The vertical axis represents fluorescence detection intensity, and the horizontal axis represents elapsed time.

  Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the following preferred embodiments, and can be freely modified within the scope of the present invention.

Bifidobacterium (hereinafter referred to as “bifidobac”
teria) ". ) Is one of the dominant bacterial species of the intestinal flora formed in the human intestinal tract. In normal healthy individuals, 5-20% of enterobacteria are present in bifidobacteria.
Bifidobacteria produce lactic acid and acetic acid in a ratio of 2: 3. These acids promote peristaltic movement of the large intestine, suppress harmful bacteria such as Escherichia coli and Clostridium perfringens, and suppress spoilage products. Is thought to be appropriate. Bifidobacteria are known to have an immune enhancing action, a carcinogenesis-inhibiting action, and the like in addition to the above-mentioned bowel regulating action. For this reason, in recent years, with an increase in the health orientation of consumers, demand for foods containing living bifidobacteria such as fermented milk containing bifidobacteria has increased.

  Although it is known that D-amino acids exist in the cells of bifidobacteria (Non-patent Document 7), bifidobacteria secrete D-amino acids into the medium, and in particular species, It has not been known so far that the secretion amount of D-form is much higher than that of L-form.

Bifidobacterium genus bacteria used in the present invention are not particularly limited, but include Bifidobacterium longum species, Bifidobacterium breve species, and Bifidobacterium bifidum. (Bifidobacterium bifidum) species, Bifidobacterium adolescentis species, and Bifidobacterium infantis, Bifidobacterium longum subspecies infantitis ) Species.
These bacteria can be purchased, for example, from the American Type Culture Collection (address 10801 University Boulevard, Manassas, VA 20110, United States of America).

  Among the bacteria belonging to the genus Bifidobacterium, Bifidobacterium longum ATCC 15707 (reference strain), Bifidobacterium longum ATCC BAA-999, Bifidobacterium breve FERM BP-11175, Bifidobacterium breve It is preferable to use NITE BP-1253, Bifidobacterium bifidum NITE BP-1252, Bifidobacterium bifidum MCC1092.

  Bifidobacterium longum ATCC 15707 and Bifidobacterium longum ATCC BAA-999 can be obtained from the American Type Culture Collection.

Bifidobacterium breve FERM BP-11175 was issued on August 25, 2009 at the National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center (currently the National Institute for Product Evaluation Technology Patent Microorganism Depositary: 292-〒) 0818, Kazusa Kamashizu, Chisarazu City, Chiba Prefecture, 2-5-8), based on the Budapest Treaty (Accession Number: FERM)
BP-11175).

  Bifidobacterium breve NITE BP-1253 was internationally deposited based on the Budapest Treaty on February 23, 2012, at the Patent Microorganism Depositary, National Institute of Technology and Evaluation (Accession No. NITE BP-1253). ).

  Bifidobacterium bifidum NITE BP-1252 was internationally deposited under the Budapest Treaty on February 23, 2012 at the Center for Patent Microbiology Deposits of the National Institute of Technology and Evaluation (Accession Number NITE BP-1252). ).

The Bifidobacterium to be used can be selected according to the type of D-amino acid to be produced. For example, when the purpose is to obtain a large amount of D-amino acid regardless of the amount of L-amino acid, a species having a particularly large amount of secreted D-amino acid is selected from among the bacteria belonging to the genus Bifidobacterium. It is preferable.

On the other hand, when aiming to obtain only D-amino acids while suppressing the contamination of L-amino acids as much as possible, it is preferable to use a species having a higher secretion amount of D-form than L-form.
For example, the value calculated by the formula [D-amino acid secretion amount] / ([D-amino acid secretion amount] + [L-amino acid secretion amount]) is 0.5 or more, preferably 0.8 or more, more preferably It is possible to produce D-amino acids with high efficiency by using Bifidobacterium belonging to 1.0. As long as the secretory unit in the denominator in the formula and the secretory unit in the numerator in the formula are the same, the amino acid secretion applied to the above formula is a value expressed in any unit. Good.

  From the viewpoint of the secretion amount and secretion ratio of D-amino acid, it is preferable to use Bifidobacterium longum species, Bifidobacterium breve species, Bifidobacterium bifidum species.

The medium used in the present invention may be any medium as long as it can cultivate Bifidobacterium, and can be appropriately selected from known media. Specifically, MRS (de Man, Rogosa Sharpe) medium, ABCM (anaerobic bacterial culture medium) medium, RCA
(Reinforced clostridial agar) medium, BL (Blood Liver) medium, TOS propionic acid medium, GAM (Gifu Anaerobic Medium) medium, EG (Eggerth-Gagnon) medium, and the like.

  As the culturing step in the present invention, known culturing conditions capable of culturing Bifidobacterium are employable. For example, it is possible to cultivate anaerobically at 25 to 45 ° C., but culturing at 30 to 42 ° C., particularly 37 to 42 ° C., is preferable because Bifidobacterium bacteria grow well. The culture time can be adjusted as appropriate while observing the growth rate between 12 and 72 hours. However, when the culture time is 16 to 48 hours, particularly 16 to 24 hours, the growth of Bifidobacterium is in a stationary phase. This is preferable because the production amount of D-amino acid reaches the maximum.

  The D-amino acid secreted into the medium and the bacteria are separated from the culture medium cultured by the culture process as described above, and the fraction containing the D-amino acid is recovered from the medium. The separation of D-amino acid and bacteria and the collection of the fraction containing D-amino acid from the medium may be carried out simultaneously, and after removing the bacteria from the medium, the fraction containing D-amino acid is removed from the medium. It may be recovered.

  Examples of the step of separating bacteria from the medium include filtration with a membrane and centrifugation. The membrane may be either a flat membrane or a hollow fiber membrane (hollow fiber). When filtration is performed using a hollow fiber membrane (hollow fiber), the separation of D-amino acid and bacteria and the recovery of the fraction containing D-amino acid from the medium can be performed simultaneously.

  Moreover, as a process which collect | recovers the fractions containing D-amino acid from the culture medium which removed bacteria, the method known about L-amino acid can be employ | adopted, for example, various types, such as ion exchange, gel filtration, a reverse phase, etc. Examples of the method include chromatography, salting out, crystallization, and solvent precipitation. These methods can be appropriately selected depending on the type of D-amino acid that is the object. Chromatography may be low pressure or high pressure (HPLC).

The fraction containing D-amino acid is not particularly limited as long as it does not impair the effect of D-amino acid and does not contain bacterial cells, may contain a medium component, and is completely or partially purified. There may be. Purification of D-amino acids can be performed by appropriately combining the methods for recovering the above-mentioned fractions containing D-amino acids.
The properties of the fraction containing D-amino acid are not particularly limited, and may be a liquid or a powder obtained by lyophilization or the like.

The fraction containing D-amino acid may contain L-amino acid as long as the effect of D-amino acid is not impaired, but even if only D-amino acid is separated and purified using a known separation and purification method. Good. Separation of D-amino acid and L-amino acid can be performed, for example, by appropriately selecting a diastereomer method, an enzyme method, chromatography, or the like, or by combining these methods (Patent Document 6, Non-patent document 8, Non-patent document 9).
The chromatography may be appropriately selected from those known as methods for separating optical isomers, for example, forming a diastereomeric complex with an optically active component bonded to a stationary phase. The chiral stationary phase method for fractionating the desired enantiomer, the chiral mobile phase method by adding an appropriate optically active compound to the mobile phase solvent, and the reaction of the enantiomer with an appropriate optically active derivatization reagent. Separation and purification of D-amino acids can be performed by appropriately combining a chiral derivatization method or the like that is subjected to a normal separation system after conversion to a stereomer.

  The D-amino acid produced according to the present invention is not only expected to have the physiological action of D-amino acid, but also for various purposes such as taste masking, etc. Can be blended into the product.

  The D-amino acid produced according to the present invention can be used as a pharmaceutical, a quasi-drug, or an active ingredient thereof as one aspect, and the D-amino acid is used as it is, or the D-amino acid is pharmaceutically acceptable. In combination with a pharmaceutical carrier, it can be administered to mammals including humans orally or transdermally.

  The pharmaceutical or quasi-drug formulation form is not particularly limited, and includes tablets (including sugar-coated tablets, enteric-coated tablets, buccal tablets), powders, capsules (including enteric capsules and soft capsules), granules (coated). ), Pills, troches, encapsulated liposomes, solutions, ointments, or pharmaceutically acceptable sustained release formulations thereof.

In formulation, additives such as carriers, excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents, diluents, surfactants, solvents, etc. that are widely used in ordinary formulations as formulation components Can be used. The D-amino acid may be used in combination with other drugs or quasi drugs.
The drug or quasi-drug used together may be contained as one of the active ingredients in the preparation containing D-amino acid, or may be commercialized as a separate preparation without being contained in the preparation. .

  Carriers and excipients used in the above pharmaceuticals or quasi drugs include lactose, glucose, sucrose, mannitol, potato starch, corn starch, calcium carbonate, calcium phosphate, calcium sulfate, crystalline cellulose, licorice powder, gentian powder, etc. Examples of the binder include starch, gelatin, syrup, polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, hydroxypropyl cellulose, ethyl cellulose, methyl cellulose, carboxymethyl cellulose, and the like.

  Examples of the disintegrant include starch, agar, gelatin powder, sodium carboxymethyl cellulose, carboxymethyl cellulose calcium, crystalline cellulose, calcium carbonate, sodium bicarbonate, and sodium alginate.

  Furthermore, examples of lubricants include magnesium stearate, hydrogenated vegetable oil, and macrogol, and examples of colorants include red No. 2, yellow No. 4, and blue No. 1 that are allowed to be added to pharmaceuticals. can do.

  Tablets and granules are sucrose, hydroxypropylcellulose, purified shellac, gelatin, sorbitol, glycerin, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, cellulose phthalate acetate, hydroxypropylmethylcellulose phthalate, methyl methacrylate as necessary And a methacrylic acid polymer.

  When blended in cosmetics, additives that can be used in ordinary cosmetics can be blended and prepared in various forms within a range that does not impair the effects of D-amino acids. For example, it can be in the form of cosmetics applied to the skin such as lotion, cream, foundation, milky lotion, or the form applied to the skin such as bathing agent.

  When blended in foods and drinks, the form and properties are not particularly limited as long as they can be taken orally without impairing the effects of D-amino acids. Can do. Moreover, since the bacteria belonging to the genus Bifidobacterium used in the present invention are so-called bifidobacteria with a long dietary experience, it is possible to add a fraction containing bacteria as it is.

  Foods such as the above, in the form of liquids, pastes, gels, powders, etc., in addition to tablet confectionery, liquid foods, etc., for example, bread, macaroni, spaghetti, noodles, cake mix, fried flour Wheat flour products such as bread crumbs; instant noodles, cup noodles, retort / cooked food, canned food, microwave food, instant soup / stew, instant miso soup / soup, canned soup, freeze-dried food, other instant foods Agricultural processed products such as canned agricultural products, canned fruits, jams and marmalades, pickles, boiled beans, dried agricultural products, cereals (cereal processed products); canned marine products, fish ham and sausages, marine products, marine delicacy, Tsukudani Processed fishery products such as fish; processed livestock products such as livestock canning and pasting, livestock ham and sausage; processed milk, milk drinks, yogurts, milk Milk and dairy products such as fungi beverages, cheese, ice cream, formula milk powder, cream and other dairy products; fats and oils such as butter, margarines, vegetable oils; soy sauce, miso, sauces, tomato processed seasonings, Basic seasonings such as mirin, vinegar, etc .; cooking mixes, curry ingredients, sauces, dressings, noodle soups, spices, and other complex seasonings and foods; frozen foods, semi Frozen foods such as cooked frozen foods and cooked frozen foods; caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pie, snacks, crackers, Japanese confectionery, rice confectionery, bean confectionery, dessert confectionery, jelly, other confectionery, etc. Confectionery: carbonated drinks, natural fruit juice, fruit juice drinks, soft drinks with fruit juice, fruit drinks, fruit drinks with fruit granules, vegetable drinks, soy milk, soy milk Beverages, coffee beverages, tea beverages, powdered beverages, concentrated beverages, sports beverages, nutritional beverages, alcoholic beverages, other beverages such as other favorite beverages, baby food, sprinkles, other commercially available foods such as tea crush paste, etc .; Examples include infant formulas; enteral nutrition; functional foods (special health foods, nutritional functional foods) and the like.

Further, the D-amino acid can be contained in the feed.
The form of the feed is not particularly limited, for example, grains such as corn, wheat, barley, rye, milo; vegetable oils such as soybean oil meal, rapeseed oil meal, coconut oil meal, linseed oil meal; bran, wheat straw, rice bran, Dehydrated rice bran, etc .; Manufactured deer such as corn gluten meal, corn jam meal; Animal feed such as fish meal, non-fat dry milk, whey, yellow grease, tallow; Yeasts such as torula yeast, beer yeast; It can be produced by blending mineral feed such as calcium phosphate and calcium carbonate; fats and oils; simple amino acids; sugars and the like. Examples of the form of the feed include pet food, livestock feed, and fish feed.

  Hereinafter, the present invention will be described more specifically with reference to examples. However, the present invention is not limited to these examples.

[Example 1]
As bacteria belonging to the genus Bifidobacterium, Bifidobacterium longum ATCC BAA-999, Bifidobacterium longum ATCC 15707 (obtained from ATCC), Bifidobacterium breve FERM BP-11175, Bifido The bacteria Breve NITE BP-1253, Bifidobacterium bifidum NITE BP-1252, and Bifidobacterium bifidum MCC1092 were respectively converted into MRS (de Man Rogasa Sharpe) medium (Difco® product, Becton Dickinson) 3 mL) and anaerobically cultured at 37 ° C overnight (16 hours). The medium was filtered through a 0.22 μm filter to remove the cells, and the obtained culture supernatant was stored in a refrigerator.
For Bifidobacterium bifidum MCC1092, a strain isolated from the feces of human infants by the applicant was used in this example.

The amino acid in the culture supernatant was converted to a fluorescent derivative using 4-Fluoro-7-nitro-2,1,3-benzoxadiaxole (NBD-F) and analyzed by HPLC. Specifically, 1 mL of the culture supernatant was air-dried under reduced pressure, and the obtained solid content was dissolved in 20 μL of sodium borate buffer (pH 8.2). Subsequently, 5 μL of 40 mM NBD-F / acetonitrile solution was added, incubated at 60 ° C. for 2 minutes, and 2 μL of the reaction solution dissolved in 75 μL of 2% trifluoroacetic acid aqueous solution was subjected to HPLC.

HPLC was mainly performed by an HPLC system composed of a first dimension using a reverse-phase microcolumn and a second dimension using an optical isomer separation column.
The configuration of the HPLC system used (NANOSPACE SI-2 series, Shiseido, Japan) is shown below.
3010 type deaerator,
2 3201 type pumps,
3033 type autosampler,
3004 type column oven,
Two 3013 type fluorescence detectors,
3012 type column selection unit, multi-loop unit (9 loops, 1 loop length 750
mm x ID 0.5 mm, 150 μL capacity per loop), 1 input to 10 output valve (C5-2340 EMTD, Valco Instruments, USA).
The data processing program EzChrom Elite Client was used to monitor the detector response, and the column selection unit and multi-loop unit were controlled using a KSAA valve control system (Shiseido).

In the first dimension, a microbore-monolithic ODS column (length 1000 mm x inner diameter 0.53 mm, packed with silica gel, manufactured by Shiseido) was used while being maintained at 45 ° C. As the mobile phase, an aqueous solution containing 6% acetonitrile and 0.06% trifluoroacetic acid was used at a flow rate of 25 μL per minute.

In the second dimension, a narrowbore-Sumichiral OA-2500S optical isomer separation column (length 250 mm x inner diameter 1.5 mm, Sumika Chemical, Japan) was used at 25 ° C.
For the mobile phase of Asn and Ser, a 5 mM citrated / methanol / acetonitrile mixture (25:75 mixture) was used at a flow rate of 200 μL per minute.
For the mobile phase of Glu and Asp, 2.5 mM citrate / methanol / acetonitrile mixture (25
: 75 mixture) was used at a flow rate of 200 μL per minute.
As the His mobile phase, 0.5 mM citrated methanol was used at a flow rate of 200 μL / min.
For Pro, 5 mM citrate / methanol was used at a flow rate of 200 μL / min, and for Ala, a 5 mM citrate / methanol / acetonitrile mixture (50:50 mixture) was used at a flow rate of 200 μL / min.

The reaction solution containing the derivatized amino acid was applied to a reversed-phase microcolumn in the first dimension.
Then, the fluorescence of the NBD derivatized amino acid with an excitation wavelength of 470 nm was detected at 530 nm by a fluorescence detector installed in the first dimension, and the fraction containing the detected amino acid (the state of the mixture of D-form and L-form: FIG. 1) was introduced into the optical isomer separation column in the second dimension by column switching and separated, and D-form and L-form were quantified by a fluorescence detector installed in the second dimension (FIG. 2).
Table 1 shows the results of quantification of D-amino acids and L-amino acids.

Table 1 shows the amino acid secretion amount calculated by subtracting the amino acid content contained in the MRS medium before culture from the amino acid content in the medium after each bacterial culture.
When the amount of secretion is negative, it indicates that the amount of amino acids in the medium consumed by the bacteria is greater than the amount of amino acids secreted by the bacteria during the culture. It shows that the amount of amino acids secreted by the bacteria during culture was greater than the amount consumed by the bacteria.

  Table 1 shows that Bifidobacterium bacteria secreted D-histidine, D-asparagine, D-proline, D-serine, D-aspartic acid, D-glutamic acid, and D-alanine.

Table 2 below shows the secretion ratio of D-amino acid in each bacterium from the results of Table 1, [D
-Amino acid secretion amount] / ([D-amino acid secretion amount] + [L-amino acid secretion amount]). However, when the amount of secreted D-amino acid or the amount of secreted L-amino acid was a negative value, the amount of secretion was calculated as 0.

In Bifidobacterium longum, the secretion ratio of D-asparagine and D-proline was 0.5 or more, and it was found that D-amino acids were secreted with high efficiency.
In Bifidobacterium breve, the secretion ratio of D-histidine, D-asparagine and D-alanine was 0.5 or more, and it was found that D-amino acids were secreted with high efficiency.
In Bifidobacterium bifidum, the secretion ratio of D-histidine, D-asparagine and D-serine was 0.5 or more, and it was found that D-amino acids were secreted with high efficiency.

The D-amino acid produced in the present invention can be widely used in medicine, quasi-drugs, cosmetics, foods, feeds, etc. for the purpose of the physiological effect of D-amino acids or for taste-masking purposes. is there.
Moreover, in the production method of the present invention, it is possible to produce a D-amino acid with high efficiency by employing a specific species.

1 shows the peak of serine in a state where D-form and L-form are mixed.
2 Shows the peak of D-serine.
The peak of 3 L-serine is shown.

Claims (3)

Culturing bacteria belonging to the genus Bifidobacterium in a medium; and
Separating the D-amino acid secreted into the culture medium after the culture and the bacteria, and recovering a fraction containing the D-amino acid from the medium;
A method for producing a D-amino acid, comprising:
The manufacturing method of D-amino acid which is any of following (a)-( d ).
(A) The bacterium belonging to the genus Bifidobacterium is Bifidobacterium longum ATCC BAA-999, and the D-amino acid is D-proline .
(B ) The bacterium belonging to the genus Bifidobacterium is Bifidobacterium breve NITE BP-1253, and the D-amino acid is selected from the group consisting of D-histidine and D-asparagine or Multiple D-amino acids.
( C ) The bacterium belonging to the genus Bifidobacterium is Bifidobacterium breve FERM BP-11175, wherein the D-amino acid is selected from the group consisting of D-asparagine and D-alanine or Multiple D-amino acids.
( D ) The bacterium belonging to the genus Bifidobacterium is Bifidobacterium bifidum NITE BP-1252, wherein the D-amino acid is selected from the group consisting of D-histidine and D-serine Multiple D-amino acids.   The production method according to claim 1, wherein the fraction containing the D-amino acid is collected from the medium after removing the bacteria from the medium. The production method according to claim 1 or 2, wherein the fraction containing the D-amino acid satisfies the following relational expression (1).
[D-amino acid secretion amount] / ([D-amino acid secretion amount] + [L-amino acid secretion amount]) ≧ 0.5 (1)